International Stem Cell (ISCO) Profit After Tax (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Profit After Tax of -$348000.0 for Q4 2025, down 3263.64% year-over-year from $11000.0 in Q4 2024, and down 710.53% quarter-over-quarter from $57000.0 in Q3 2025.
International Stem Cell (ISCO) Profit After Tax (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Profit After Tax for 16 consecutive years, with -$348000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Profit After Tax fell 3263.64% year-over-year to -$348000.0; the TTM figure through Dec 2025 stood at -$418000.0 (down 100.0% YoY), while the FY2025 annual figure was -$418000.0, down 100.0% from the prior year.
- Profit After Tax retreated to -$348000.0 in Q4 2025 per ISCO's latest filing, from $57000.0 in the prior quarter.
- Across five years, Profit After Tax topped out at $492000.0 in Q2 2023 and bottomed at -$599000.0 in Q1 2021.
- Historically, Profit After Tax has averaged -$91650.0 across 5 years, with a median of -$79500.0 in 2023.
- Annual changes were most pronounced in 2023 — Profit After Tax jumped 24700.0% — and 2025, when it plunged 3263.64%.
- International Stem Cell's Profit After Tax stood at -$351000.0 in 2021, then soared by 106.55% to $23000.0 in 2022, then slumped by 1417.39% to -$303000.0 in 2023, then surged by 103.63% to $11000.0 in 2024, then slumped by 3263.64% to -$348000.0 in 2025.
- Business Quant data shows ISCO's Profit After Tax at -$348000.0 in Q4 2025, $57000.0 in Q3 2025, and $129000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | International Stem Cell | 3.76 Mn | 2.67 Mn | 1.46 Mn | -71,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -71,000.00 |
| Dec 31, 2025 | -348,000.00 |
| Sep 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 129,000.00 |
| Mar 31, 2025 | -256,000.00 |
| Dec 31, 2024 | 11,000.00 |
| Sep 30, 2024 | -125,000.00 |
| Jun 30, 2024 | 119,000.00 |
| Mar 31, 2024 | -214,000.00 |
| Dec 31, 2023 | -303,000.00 |
| Sep 30, 2023 | -131,000.00 |
| Jun 30, 2023 | 492,000.00 |
| Mar 31, 2023 | -34,000.00 |
| Dec 31, 2022 | 23,000.00 |
| Sep 30, 2022 | -343,000.00 |
| Jun 30, 2022 | -2,000.00 |
| Mar 31, 2022 | -9,000.00 |
| Dec 31, 2021 | -351,000.00 |
| Sep 30, 2021 | -165,000.00 |
| Jun 30, 2021 | 216,000.00 |